Literature DB >> 3310850

The c-K-ras gene and human cancer (review).

S Kahn1, F Yamamoto, C Almoguera, E Winter, K Forrester, J Jordano, M Perucho.   

Abstract

A significant number of human tumors from diverse histological origins contain c-K-ras oncogenes which have been activated by somatic point mutations resulting in single amino acids substitutions in the encoded p21 ras protein. In addition to these qualitative changes, other genetic alterations leading to increased expression of the c-K-ras gene, especially its mutated form, appear to be important in the activation of its oncogenic potential. These findings support the hypothesis that c-K-ras oncogenes are contributing in a dominant but dose dependent manner to the multistage process of human tumorigenesis. Activated c-K-ras oncogenes have been detected in human tumors at different stages of progression, including premalignant neoplasms. These studies provide evidence for the involvement of somatic mutational activation of this ras gene in the early stages of tumor development in some types of human cancer. We discuss here the structural and functional features of the human c-K-ras gene and the involvement of its activated form in human cancer.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3310850

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  12 in total

1.  Five-year survival of metastatic pancreatic carcinoma: a study of courage and hope.

Authors:  Ben M Chue
Journal:  Gastrointest Cancer Res       Date:  2009-09

2.  Detection of a rare point mutation in Ki-ras of a human bladder cancer xenograft by polymerase chain reaction and direct sequencing.

Authors:  S M Grimmond; D Raghavan; P J Russell
Journal:  Urol Res       Date:  1992

3.  High sequence similarity within ras exons 1 and 2 in different mammalian species and phylogenetic divergence of the ras gene family.

Authors:  F Watzinger; B Mayr; E Haring; T Lion
Journal:  Mamm Genome       Date:  1998-03       Impact factor: 2.957

4.  Nutritional limitation sensitizes mammalian cells to GSK-3β inhibitors and leads to growth impairment.

Authors:  Paola de Candia; Giuseppina Minopoli; Viola Verga; Anna Gargiulo; Marco Vanoni; Lilia Alberghina
Journal:  Am J Pathol       Date:  2011-04       Impact factor: 4.307

5.  Sarcolemmal targeting of nNOSμ improves contractile function of mdx muscle.

Authors:  Daniela L Rebolledo; Min Jeong Kim; Nicholas P Whitehead; Marvin E Adams; Stanley C Froehner
Journal:  Hum Mol Genet       Date:  2015-11-24       Impact factor: 6.150

6.  The Drosophila Ral GTPase regulates developmental cell shape changes through the Jun NH(2)-terminal kinase pathway.

Authors:  K Sawamoto; P Winge; S Koyama; Y Hirota; C Yamada; S Miyao; S Yoshikawa; M H Jin; A Kikuchi; H Okano
Journal:  J Cell Biol       Date:  1999-07-26       Impact factor: 10.539

7.  Glutamine deprivation induces abortive s-phase rescued by deoxyribonucleotides in k-ras transformed fibroblasts.

Authors:  Daniela Gaglio; Chiara Soldati; Marco Vanoni; Lilia Alberghina; Ferdinando Chiaradonna
Journal:  PLoS One       Date:  2009-03-05       Impact factor: 3.240

8.  Identification of potential diagnostic markers of prostate cancer and prostatic intraepithelial neoplasia using cDNA microarray.

Authors:  J H Bull; G Ellison; A Patel; G Muir; M Walker; M Underwood; F Khan; L Paskins
Journal:  Br J Cancer       Date:  2001-06-01       Impact factor: 7.640

9.  Negative regulation of p120GAP GTPase promoting activity by p210bcr/abl: implication for RAS-dependent Philadelphia chromosome positive cell growth.

Authors:  T Skorski; P Kanakaraj; D H Ku; M Nieborowska-Skorska; E Canaani; G Zon; B Perussia; B Calabretta
Journal:  J Exp Med       Date:  1994-06-01       Impact factor: 14.307

10.  Diagnosis of pancreatic adenocarcinoma by polymerase chain reaction from pancreatic secretions.

Authors:  L H Trümper; B Bürger; F von Bonin; A Hintze; G von Blohn; M Pfreundschuh; H Daus
Journal:  Br J Cancer       Date:  1994-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.